Estrogen-receptor positive human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated w/ endocrine therapy; locally advanced or metastatic breast cancer in postmenopausal women w/ disease relapse on or after adjuvant endocrine therapy, or disease progression on endocrine therapy.
Adult female including elderly 500 mg at 1-mth intervals w/ additional 500-mg dose given 2 wk after initial dose, administered 1 in each buttock as 2 consecutive 5 mL slow IM inj.
Bleeding diatheses, thrombocytopenia; thromboembolic events; potential risk of osteoporosis. Dorsogluteal inj site due to proximity of underlying sciatic nerve. Interfered Ab-based estradiol assays. Concomitant use w/ anticoagulants. May affect ability to drive & use machines. Mild to moderate hepatic impairment. Severe renal impairment (CrCl <30 mL/min). Women of childbearing potential should use effective contraception. Not to be used during pregnancy & lactation. Not to be used in neonates. Avoid use in childn <2 yr. Not recommended in childn or adolescents.
Manage Account
Change Password
Sign Out
